Home AffyXell Therapeutics

AffyXell Therapeutics

In operation
Series A
Novel Mesenchymal Stem Cell (MSC) Therapy Developer
Basic
Enterprise Profile

Basic Information

AffyXell Therapeutics is a joint venture established by Avacta Group and Daewoong Pharmaceutical. AffyXell Therapeutics primarily focuses on inflammation and autoimmune diseases, dedicated to developing novel mesenchymal stem cell (MSC) therapies.
AffyXell Therapeutics
Seoul,SeoulSpecialCity,SouthKorea
less than 15 people
January 01, 2020
--
--

Enterprise Profile

Industrial Sector
New Drug Development Manufacture of Biological Pharmaceutical Products Immune Cell Therapy
Technology
Cell Technology Stem Cell Technology
Concept
Immune System Diseases Therapeutic Products
Application Scenarios
Innovative Drugs Biological Products Cell and Gene Therapy